Transgene

Transgene Current Liabilities

The Current Liabilities of Transgene (TNG.PA) as of Oct 8, 2026 is 13.98 M EUR. In the previous year, Current Liabilities was 10.04 M EUR — a change of 39.26% (higher).

Current Liabilities

13.98 MEUR

YoY

39.26%

Last updated:

Current Liabilities of Transgene is 2024 13.98 M EUR. Current Liabilities of Transgene was 2023 10.04 M EUR. It decreases by 39.26% higher compared to the previous year.

The Transgene Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
16.87 M EUR
Jan 1, 2018
19.64 M EUR
Jan 1, 2019
18.65 M EUR
Jan 1, 2020
13.63 M EUR
Jan 1, 2021
14.59 M EUR
Jan 1, 2022
12.78 M EUR
Jan 1, 2023
10.04 M EUR
Jan 1, 2024
13.98 M EUR
The Transgene Current Liabilities history
YEARCurrent LiabilitiesYoY
13.98 MEUR+39.26%
10.04 MEUR-21.44%
12.78 MEUR-12.39%
14.59 MEUR+7.04%
13.63 MEUR-26.91%
18.65 MEUR-5.08%
19.64 MEUR+16.47%
16.87 MEUR-15.33%
19.92 MEUR-25.47%
26.73 MEUR+23.94%
21.56 MEUR-10.15%
24.00 MEUR+23.08%
19.50 MEUR-7.14%
21.00 MEUR+12.90%
18.60 MEUR+66.07%
11.20 MEUR-26.80%
15.30 MEUR+35.40%
11.30 MEUR+36.14%
8.30 MEUR+38.33%
6.00 MEUR+11.11%
5.40 MEUR+1.89%
5.30 MEUR-1.85%
5.40 MEUR-14.29%
6.30 MEUR-3.08%
6.50 MEUR+18.18%
5.50 MEUR0.00%
5.50 MEUR+52.78%
3.60 MEUR+0.00%
3.60 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Current Liabilities of Transgene is 13.98 M EUR in 2024.

Current Liabilities of Transgene changed from 10.04 M EUR to 13.98 M EUR, representing a 39.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Transgene since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Transgene historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Transgene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene